Last Updated: 15 Sep 2024
Executive Summary
Takeda Pharmaceutical Co Ltd ADR (TAK) is a leading global pharmaceutical company with a market capitalization of $46.59 billion. The company has a strong financial position with an EBITDA of $117.43 billion and a profit margin of 3.4%. TAK's dividend yield is 0.0398% and its EPS is $0.33. The company's stock price has been trading within a range of $12.57 and $15.73 over the past 52 weeks.
Company Overview
Takeda Pharmaceutical Co Ltd ADR is a research-based global biopharmaceutical company that focuses on four therapeutic areas: Oncology, Gastroenterology, Neuroscience, and Rare Diseases. The company has a global presence with operations in over 80 countries. Takeda's mission is to provide innovative medicines that improve the lives of patients around the world.
Fundamental Analysis
Takeda Pharmaceutical Co Ltd ADR has a strong financial position with an EBITDA of $117.43 billion and a profit margin of 3.4%. The company's revenue has grown by 14.1% over the past year and its EPS has grown by 4.9%. Takeda's balance sheet is also strong with a debt-to-equity ratio of 0.49.
Technical Analysis
Takeda Pharmaceutical Co Ltd ADR's stock price has been trading within a range of $12.57 and $15.73 over the past 52 weeks. The stock price is currently trading at $14.7, which is above its 50-day and 200-day moving averages. The relative strength index (RSI) is 55.02, which indicates that the stock is neither overbought nor oversold.
Short Term Outlook
Takeda Pharmaceutical Co Ltd ADR's stock price is expected to continue to trade within a range in the short term. The stock price is likely to be supported by the company's strong financial position and its pipeline of new drugs. However, the stock price could be pressured by the company's exposure to the US market, which is facing increasing pricing pressure.
Long Term Outlook
Takeda Pharmaceutical Co Ltd ADR's long-term outlook is positive. The company is well-positioned to benefit from the growing demand for pharmaceuticals in emerging markets. The company's pipeline of new drugs is also expected to drive growth in the coming years.
Analyst Recommendations
Analysts have a mixed view on Takeda Pharmaceutical Co Ltd ADR. One analyst has a Strong Buy rating on the stock, two analysts have a Buy rating, one analyst has a Hold rating, and no analysts have a Sell or Strong Sell rating. The average analyst target price is $17.05.
